ChemRxiv
These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
manuscript.docx (625.82 kB)
0/0

Drug Repurposing to Identify Therapeutics Against COVID 19 with SARS-Cov-2 Spike Glycoprotein and Main Protease as Targets: An in Silico Study

preprint
submitted on 07.04.2020 and posted on 10.04.2020 by arun kumar, Sharanya C.S, Abhithaj J, Sadasivan C

The total cases of novel corona virus (SARS-CoV-2) infections is more than one million and total deaths recorded is more than fifty thousand. The research for developing vaccines and drugs against SARS-CoV-2 is going on in different parts of the world. Aim of the present study was to identify potential drug candidates against SARS-CoV-2 from existing drugs using in silico molecular modeling and docking. The targets for the present study was the spike protein and the main protease of SARS-CoV-2. The study was able to identify some drugs that can either bind to the spike protein receptor binding domain or the main protease of SARS-CoV-2. These include some of the antiviral drugs. These drugs might have the potential to inhibit the infection and viral replication.

History

Email Address of Submitting Author

arunsrnd@gmail.com

Institution

kannur university

Country

India

ORCID For Submitting Author

0000-0002-2502-1719

Declaration of Conflict of Interest

no conflict of interest

Exports

Logo branding

Exports